Trial Information

Summary: Osteoarthrtis of the Knee Study Patch

Over 43 million Americans suffer with Osteoarthritis, especially in the knees. Tampa Bay Medical Research is enrolling in a research study testing a topical patch to treat mild to moderate pain associated with osteoarthritis of the knee.

Qualified participants will receive all study related medical exams, study patch, and lab tests at no cost. You may be compensated for time and travel. No insurance is necessary.

Patient Inclusion Criteria:

  • Participants must be at least 18 to 75 years old.
  • Participants must be diagnosed with Osteoarthritis

Patient Exclusion Criteria:

  • Participants must not be allergic to NSAID's.
  • Participants must not be allergic to adhesive bandages.
  • Participants must be in general good health.
  • Participants must not have had recent knee injury and/or surgery.

Contact:

Thalia Morgan, Marketing
Tampa Bay Medical Research, Inc
3251 McMullen Booth Road, Suite 301
Clearwater, FL 33761
Telephone: 727-724-3316, ext.108
Fax: 727-725-5561
Email:

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:33:41 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA